B Cell Suppression in Newborn Following Treatment of Pregnant Diffuse Large B-cell Lymphoma Patient with Rituximab Containing Regimen

Indian Journal of Pediatrics

Volumn 81, Issue 10, 2014, Pages 1092-1094

  Mandal, Prakas Kumar ^a   Dolai, Tuphan Kanti ^a   Bagchi, Basab ^a   Ghosh, Malay Kumar ^a   Bose, Sudipta ^b   Bhattacharyya, Maitreyee ^a  

^a NRS MEDICAL COLLEGE   (India)

^b MIDNAPORE MEDICAL COLLEGE AND HOSPITAL   (India)

Author keywords

B cell suppression; Diffuse large B cell lymphoma; Rituximab

Indexed keywords

CD20 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; HEMOGLOBIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LACTATE DEHYDROGENASE; PREDNISOLONE; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT;

ADULT; AGE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CASE REPORT; CESAREAN SECTION; DISEASE DURATION; FATIGUE; FEMALE; FETUS ECHOGRAPHY; FLOW CYTOMETRY; FOLLOW UP; GENERALIZED LYMPHADENOPATHY; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMORAL IMMUNE DEFICIENCY; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; LACTATE DEHYDROGENASE BLOOD LEVEL; LARGE CELL LYMPHOMA; LEUKOCYTE COUNT; LOW BACK PAIN; LYMPHOCYTE COUNT; MONOCYTE; MULTIPLE CYCLE TREATMENT; NEUTROPHIL COUNT; NEWBORN DISEASE; PALLOR; PATIENT COUNSELING; PREGNANCY DISORDER; PREGNANCY OUTCOME; PRIMIGRAVIDA; RISK FACTOR; THROMBOCYTE COUNT; B LYMPHOCYTE; CYTOLOGY; DRUG EFFECTS; FETUS BLOOD; LYMPHOMA, LARGE B-CELL, DIFFUSE; NEWBORN; PREGNANCY; PREGNANCY COMPLICATIONS, NEOPLASTIC;

ADULT; ANTINEOPLASTIC AGENTS; B-LYMPHOCYTES; FEMALE; FETAL BLOOD; HUMANS; INFANT, NEWBORN; LYMPHOCYTE COUNT; LYMPHOMA, LARGE B-CELL, DIFFUSE; PREGNANCY; PREGNANCY COMPLICATIONS, NEOPLASTIC; RITUXIMAB;

EID: 84919844558     PISSN: 00195456     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12098-013-1336-9     Document Type: Article

References (9)

1. Lishner M, Zemlickis D, Sutcliffe SB, Koren G. Non-Hodgkin’s lymphoma and pregnancy. Leuk Lymphoma. 1994;14:411–3.
2. Stiehm ER, Fudenberg HH. Serum levels of immune globulins in health and disease: A survey. Pediatrics. 1966;37:715–27.
3. Chakravarty EF, Murray ER, Kelman A, Farmer P. Pregnancy outcomes following maternal exposure to rituximab. Blood. 2011;117:1499–506.
4. Muglia LJ, Katz M. The enigma of spontaneous preterm birth. N Engl J Med. 2010;362:529–35.
5. Saji F, Samejima Y, Kamiura S, Koyama M. Dynamics of immunoglobulins at the feto maternal interface. Rev Reprod. 1999;4:81–9.
6. Decker M, Rothermundt C, Holländer G, Tichelli A, Rochiltz C. Rituximab plus CHOP for treatment of diffuse large B-cell lymphoma during second trimester of pregnancy. Lancet Oncol. 2006;7:693–4.
7. Mouquet H, Musette P, Gougeon ML, Jacquot S, Lemercier B, Lim A, et al. B-cell depletion immunotherapy in pemphigus: Effects on cellular and humoral immune responses. J Invest Dermatol. 2008;128:2859–69.
8. Klink DT, van Elburg RM, Schreurs MWJ, Van Well GT. Rituximab administration in third trimester of pregnancy suppresses neonatal B-cell development. Clin Dev Immunol. 2008;2008:271–363.
9. Gupta N, Sharma S, Seth T, Mishra P, Mahapatra M, Kumar S, et al. Rituximab in steroid refractory autoimmune hemolytic anemia. Indian J Pediatr. 2012;79:803–5.